【靶点聚焦】PSMA如何扣动免疫疗法的扳机？

目前最热门的抗癌话题非CAR-T这款“治愈系”的疗法莫属。

PSMA 是双特异性抗体治疗前列腺癌的有吸引力的靶点。AMG 212 是一款靶向CD3与PSMA的双抗，一项研究入组16名mCRPC患者，被分为5个不同剂量组。在数据汇报时，3名患者的PSA水平下降了一半以上。其中一名接受了19.4个月治疗的患者，软组织转移出现了完全消退，骨转移也有明显消退然而，但是与其他靶向CD3的双特异性药物一样，AMG 212的半衰期很短，需要通过连续静脉输注给药。

The purity of Biotinylated Human PSMA, His,Avitag (Cat. No. PSA-H82Qb) was more than 85% and the molecular weight of this protein is around 190-225 kDa verified by SEC-MALS.

Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human PSMA, His Tag (Cat. No. PSA-H52H3) with a linear range of 2-39 ng/mL (QC tested).

2e5 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Biotinylated Human PSMA, His,Avitag (Cat. No. PSA-H82Qb) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routiney tested).